Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial - The Lancet

Por um escritor misterioso

Descrição

Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
JCDD, Free Full-Text
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Full article: New pharmacotherapeutic options for oral
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Poststroke Cardiovascular Management: Current Concepts, Integrated
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Anticoagulation
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Factor XIa inhibition with asundexian after acute non
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Practical “1-2-3-4-Day” Rule for Starting Direct Oral
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
PDF) The new era of anticoagulation: factor XI and XII inhibitors
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Pharmaceuticals, Free Full-Text
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Safety of the oral factor XIa inhibitor asundexian compared with
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Design and Preclinical Characterization Program toward Asundexian
Factor XIa inhibition with asundexian after acute non-cardioembolic  ischaemic stroke (PACIFIC-Stroke): an international, randomised,  double-blind, placebo-controlled, phase 2b trial - The Lancet
Safety of the oral factor XIa inhibitor asundexian compared with
de por adulto (o preço varia de acordo com o tamanho do grupo)